MedTrace Logo

Open-label Treatment in Cushing's Syndrome

NCT03621280 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2025-06-19

Study results available
· View outcomes & findings →

Summary

This is a long-term, open-label extension study of levoketoconazole in participants with endogenous Cushing's Syndrome.

Conditions

  • Cushing Syndrome
  • Cushing Disease

Interventions

DRUG

Levoketoconazole

Levoketoconazole up to 1200 mg daily

Sponsors & Collaborators

  • Cortendo AB

    lead INDUSTRY

Principal Investigators

  • Fredric Cohen, MD · Cortendo AB

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-07
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • France
  • Greece
  • Hungary
  • Israel
  • Italy
  • Netherlands
  • Poland
  • Romania
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03621280 on ClinicalTrials.gov